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Summary
BACKGROUND: Intracoronary injection of autologous
bone marrow-derived mononucleated cells (BM-MNC)
may improve LV function shortly after acute ST elevation
myocardial infarction (STEMI), but little is known about
the long-term durability of the treatment effect.
METHODS: In a single-centre trial a total of 60 patients
with acute anterior STEMI, successful reperfusion therapy
and a left ventricular ejection fraction (LVEF) of <50%
were screened for the study. 23 patients were actively
treated with intracoronary infusion of BM-MNC within a
median of 3 days. The open-label control group consisted
of 19 patients who did not consent to undergo BM-MNC
treatment but agreed to undergo regular clinical and echo-
cardiographic follow-up for up to 5 years after AMI.
RESULTS: Whereas at 4 months there was no significant
difference between the increase in LVEF in the BM-MNC
group and the control group (+7.0%, 95%CI 3.6; 10.4) vs.
+3.9%, 95%CI –2.1; 10), the absolute increase at 5 years
remained stable in the BM-MNC but not in the control
group (+7.95%, 95%CI 3.5; 12.4 vs. –0.5%, 95%CI –5.4;
4.4; p for interaction between groups = 0.035).
DISCUSSION: In this single-centre, open-labelled study,
intracoronary administration of BM-MNC is feasible and
safe in the short term. It is also associated with sustained
improvement of left ventricular function in patients with
acute myocardial infarction, encouraging phase III studies
to examine the potential BM-MNC effect on clinical out-
come.
Key words: myocardial infarction; stem cells; progenitor
cells; bone marrow; remodelling; left ventricular function
Introduction
Despite major advances in management of acute myocar-
dial infarction (AMI), maladaptive ventricular remodelling
process occurs after AMI, leading to congestive heart fail-
ure. Recently, reparative therapy by either intramyocardial
or intracoronary injection of autologous bone marrow-de-
rived mononucleated cells (BM-MNC) has been proved
to be safe and effective when administered after AMI.
First-in-man studies conducted between 2002 and 2004
demonstrated significant improvement in left ventricular
(LV) function in patients treated in the early phase after
AMI [1–4]. Several double-blind placebo controlled ran-
domised clinical trials have however shown less consistent
results in terms of improvement of left ventricular (LV)
function [5–12] (table 1).
Little is known about the long-term durability of the po-
tential therapeutic effect of regenerative BM-MNC therapy.
Assmus et al. reported the 2-year results of the Repair-
AMI trial [13] where a sustained improvement in LV func-
tion in the BM-MNC treated group could have been shown
for a subgroup of the patients undergoing cardiac magnetic
resonance imaging (CMR). Likewise, in a larger, non-ran-
domised cohort with chronic ischaemic cardiomyopathy,
Strauer et al. [14] showed that intracoronary BM-MNC
treatment had a significant effect on quality of life, im-
provement in LV function and in survival 5 years after ini-
tial treatment. In contrast, Meyer et al. recently reported
5-year results of one randomised trial showing that LV
function assessed by CMR decreased by about 3 absolute
points in both controls and a BM-MNC treated group [15].
We aimed to evaluate long-term (5 years) efficacy results
of Stem Cell Transplantation in Ischaemic Myocardium tri-
al (STIM), a single centre trial including patients with re-
cent AMI treated by intracoronary BM-MNC administra-
tion.
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Methods
60 consecutive patients with acute anterior ST-elevation
myocardial infarction (STEMI), successfully treated by
primary percutaneous coronary intervention, and initial left
ventricular ejection fraction (LVEF) <50% , were screened
to participate in a prospective single-centre evaluation
between 2004 and 2006. Of these patients, 23 (38%) agreed
to undergo intracoronary autologous BM-MNC adminis-
tration (treatment group) whereas 37 patients refused, or
had contraindications against BM-MNC therapy. Of those,
19 consented to clinical and echocardiographic data collec-
tion, serving as control group (fig. 1). Inclusion and exclu-
sion criteria are summarised in table 2. All the patients re-
ceived optimal drug therapy including ACE-inhibitors or
angiotensin-receptor II blockers, betablockers, statin, aspir-
in and clopidogrel. They underwent clinical and echocardi-
ographic follow-up at 21 days, 4 months, 12 months, and
thereafter every 12 months. All the patients gave oral and
written consent to the study. The study protocol was ap-
Table 1: Randomised clinical trials with intracoronary BM-MNC treatment in the acute phase of myocardial infarction.
Study n Cell type Modality 1° Endpoint Results
BOOST 60 BM-MNC i.c., randomised Improvement in LVEF (CMR)
at 6 months
No safety concern
Wollert et al. Lancet 2004
(6 months )
Significant improvement in LVEF
Meyer et al. Circ 2006
(18 months )
ns (improvement of control group)
Meyer et al. EHJ 2009 (5 years) Decrease of LVEF in control and
BM-MNC group
Janssens et al. 67 BM-MNC i.c., randomised, double blind Improvement in LVEF (CMR)
at 4 months
No safety concern
Lancet 2006 Placebo controlled No improvement in LVEF
Reduction of scar size (DE-CMR)
REPAIR AMI 201 BM-MNC i.c., randomised, double blind Improvement in LVEF (LV-Angio)
at 4 months
No safety concern
Schächinger et al. NEJM 2006
(4 months )
Placebo controlled Significant improvement in LVEF
Assmus et al. Circ Heart Fail
2010 (2 years)
Sustained improvement in LVEF
ASTAMI 100 BM-MNC I.c, randomised Improvement in EF (CMR)
at 6 months
No safety concern
Lunde et al. NEJM 2006 No improvement in LVEF
FINCELL study 80 BM-MNC after
thrombolysis
i.c., randomised Improvement in LVEF (LV-Angio/
echo) at 6 months
No safety concern
Huikuri et al. EHJ 2008 Significant improvement in LVEF
Plewka et al. 60 BM-MNC i.c., randomised Improvement in LVEF (echo)
at 6 months
No safety concern
Am J Cardiol. 2009 Significant improvement in LVEF
HEBE-Trial 200 BM-MNC / EPC i.c., randomised Improvement in LVEF (CMR)
at 6 months
No safety concern
Hirsch et al. EHJ 2010 No improvement in LVEF
REGENT Trial 200 BM-MNC / CD 34+ /
CXCR4+
i.c., randomised Improvement in LVEF (CMR)
at 6 months
No safety concern
Tendera et al. Eur Heart J 2009 No improvement in LVEF
BONAMI Trial 101 BM-MNC i.c., randomised Improvement in viability (SPECT) Positive in multivariate analysis
Roncalli et al. EHJ 2010 Negative in univariate analysis
Topcare AMI (5 years results) 55 BM-MNC / EPC i.c., open-labelled Assessment of LVEF (CMR)
at 5 years
No safety concern
Leistner DM et al. Clin Res
Cardiol 2011
Non-controlled Stable LVEF
Late Time 87 BM-MNC i.c., randomised; 2-3 weeks
vs. placebo
Improvement in LVEF (CMR)
at 6 months
No safety concern
Traverse JH et al. JAMA 2011 No improvement in LVEF
BM-MNC = autologous bone marrow derived mononucleated cells; i.c. = intracoronary; EPC = Endothelial progenitor cells; CD 34+/ CXCR4+ = selected mononucleated
cells co-expressing the CD 133 and the CXCR4 receptor; LVEF = left ventricular ejection fraction; CMR = cardiac magnetic resonance imaging; DE = delayed
enhancement.
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proved by local IRB and by the competent Swiss Federal
authority (“Bundesamt für Gesundheitswesen”).
Bone marrow aspiration and processing of the
mononucleated cell fraction
Bone marrow (BM) aspiration from the iliac crest was
performed under local anaesthesia and the aspirate trans-
ferred to an in-house cell processing facility (Cell Therapy
Unit of the Cardiocentro Ticino / Molecular Diagnostic
Laboratory, Lugano, CH). The mononucleated cell fraction
was isolated according to a standard protocol. Briefly, the
bone marrow was pre-filtered and then subjected to density
gradient centrifugation (ρ = 1.077 g/ml); after washing, the
cells were resuspended in 10 ml 5% v/v human albumin
Figure 1
Study design and patient recruitment. AMI: acute myocardial
infarction. PCI: percutaneous coronary intervention. i.c.:
intracoronary. BM-MNC: autologous bone marrow derived
mononucleated cells. FU: follow-up.
Figure 2
Left ventricular function directly after myocardial infarction
(baseline), after 4 and 60 months. LVEF: left ventricular ejection
fraction.
and transferred to a 10-ml syringe. An aliquot of the cell
product was collected for cell count and viability by
Neubauer chamber.
BM-MNC were reinfused at least 3 hours after BM aspira-
tion via an over-the-wire balloon catheter inserted into the
infarct related coronary artery, inflated at low pressure (2–4
bar) to completely block blood flow. This manoeuvre was
repeated three times for a total administration of 10 ml pro-
genitor cell suspension; between each injection, 5 minutes’
reflow was permitted by deflating the balloon, thus minim-
ising extensive ischaemia. After completion of intracoron-
ary cell reinfusion, coronary angiography was repeated to
ascertain vessel patency, absence of embolisation and un-
impeded flow of contrast material.
Periprocedural safety of the BM-MNC infusion was mon-
itored by assessment of serum cardiac enzymes and cardiac
troponin.
Myocardial perfusion scintigraphy
Rest gated myocardial perfusion scintigraphy (G-SPECT)
was performed the day before cell delivery and 4 months
later. Myocardial G-SPECT acquisition was performed 1 h
after IV injection of 800–925 MBq of Tc-99m-sestamibiI
using a two-head gamma camera (ECAM Siemens, Er-
langen, Germany). Sixty-four images were obtained on a
64x64 matrix for 30 seconds, throughout a 180° arc, begin-
ning from the 45° right anterior oblique projection and end-
ing at the 45° left posterior oblique projection. Transaxial
sections were used to generate oblique sections, reoriented
along the horizontal and vertical long axis and short ax-
is of the left ventricle. LVEF as well as LV enddiastolic
(LVEDV) and endsystolic (LVESV) volumes were determ-
ined using the Quantitative Gated SPECT (QGS; Cedars-
Sinai Medical Centre) program. We performed a compar-
ison between SPECT and echocardiography as for assess-
ment of LVEF by doing Lin concordance correlation.
Statistics
Continuous data were described either as median and in-
terquartile range (IQR), or as mean and standard deviation
(SD). Categorical data were expressed as counts and per-
cent. They were compared with the Student t test and the
Fisher exact test respectively. To evaluate changes over
time in LV function and compare them between groups, a
general linear regression model was fitted including time,
LV function and their interaction. Model of outcome was
the value of the LV-function measure at each time. Huber
White roust standard errors were computed to account for
intra-patient correlation. The Lin concordance correlation
coefficient was computed to assess the agreement between
SPECT and echo measurements of LVEF. All tests were
2-sided. A p-value <0.05 was considered statistically signi-
ficant. Raw p-values are presented. Bonferroni correction
for post-hoc comparisons should be applied when interpret-
ing results. Stata 11 (StataCorp, College Station, TX, USA)
was used for computation.
Results
Table 3 summarises demographic, clinical, laboratory and
echocardiographic characteristics of all patients included.
Original article Swiss Med Wkly. 2012;142:w13632
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Among the baseline characteristics there was no major dif-
ference in patient profile between the 2 groups apart from
a trend in favour of higher age and a higher frequency of
multivessel disease and more frequent use of drug eluting
Figure 3
Left ventricular remodelling directly after myocardial infarction
(baseline), after 4 and 60 months. LVEDV: left ventricular
enddiastolic volume.
Figure 4
Left ventricular remodelling directly after myocardial infarction
(baseline), after 4 and 60 months. LVESV: left ventricular
endsystolic volume.
stents in the control group. Likewise the treatment group
showed a trend towards a lower LVEF and significantly
higher volumes. The active group was treated with a mean
of 158 (80) million mononuclear cells, which were rein-
fused within a median of 3 days (IQR 2) after AMI, with
a mean cell viability of 95% (2%). No bleeding complic-
ations or haematoma formation at the iliac crest or in the
groin have been observed. TIMI flow of the former infarct
related artery was not impeded after injection of BM-MNC,
and no rise in cardiac troponin was detected. No malignant
ventricular arrhythmias were observed during the in-hos-
pital stay. Mean follow-up time was 70 months in the BM-
MNC treated group and 63 months in the untreated control
group. At 5 years follow-up (fig. 1) 21 patients were evalu-
ated in the active group (2 patients died) and 11 patients in
the control group (7 patients were lost to follow-up or un-
willing to present, 1 died 3 years after myocardial infarc-
tion).
Among the treatment group one patient died 5 months after
BM-MNC treatment for end-stage heart failure, listed for
heart transplantation. The second patient refused prophy-
lactic ICD implantation and succumbed to sudden cardiac
death 24 months after AMI.
Assessment of left ventricular function
A fair agreement between LVEF by G-SPECT analysis and
2D-transthoracic echocardiography was found at baseline
and after 4 months (Lin concordance correlation R = 85%,
95%CI 75–95%) and for long term follow up only echocar-
diography was performed (presented data derives entirely
from 2D-echocardiography; detailed data from SPECT can
be shown on request).
Baseline LV ejection fraction in both the BM-MNC treated
group and in those who refused cell treatment was moder-
ately reduced (fig. 2). At 4 months’ follow-up [16], LVEF
at echocardiography increased from 41% to 49% in the
treatment group (p <0.001) and from 45% to 49% in the
control group (p = 0.31) (fig. 2). At this time point the dif-
ference between the treatment and the control group was
not statistically significant (p = 0.27).
Table 2: Inclusion/exclusion criteria of STIM.
Inclusion criteria
STEMI with visual LVEF at angiogram or echocardiography <50% within 24 h after PCI of the IRA.
Treatment by primary PCI within 12 h of chest pain onset or initial treatment with thrombolysis within 12 h followed by PCI within 24 h of chest pain onset.
Significant regional LV wall motion dysfunction in the infarct related territory.
Age >18 years.
Exclusion criteria
Abnormal regional wall motion outside the infarct region.
Known previous myocardial infarction in the same target vessel.
Known preexisting left ventricular dysfunction (EF <50% prior to admission).
Need for revascularisation in the non infarct-related coronary within 4 months.
Preexisting symptoms of heart failure or known cardiomyopathy.
Known active infection or chronic infection with HIV, HBV or HCV..
Chronic inflammatory disease.
Serious concomitant disease with a life expectancy of less than one year.
Follow-up unlikely (no fixed abode, etc).
Severe renal failure (creatinine >250 mmol/l).
Relevant liver disease (GOT >2x norm or spontaneous INR >1.5).
Anaemia (Hb <8.5 mg/dl), thrombocytopenia (<100.000/µl).
Pregnancy.
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Long term follow-up (fig. 2; table 4) revealed stable LV
function in the BM-MNC treated group (LVEF = 49% at
60 months) whereas LV function in the untreated group
decreased to LVEF of 45%. Comparison of time profiles
between groups favours BM-MNC treatment (+8.5; 95%CI
2.1; 14.8; p value of interaction = 0.035). Likewise, neg-
ative ventricular remodelling was chiefly observed in the
control group with a significant increase in LVEDV and
LVESV, whereas in the BM-MNC treatment group both
LV enddiastolic and endsystolic volume remained stable.
Comparison of time profiles between groups favours BM-
MNC treatment with a difference of 39.7 ml for LVEDV (p
= 0.018) and 31.0 ml for LVESV (p = 0.01) (fig. 3 and 4
respectively, table 4).
Discussion
Little is known about the long-term therapeutic effect of in-
tracoronary BM-MNC injection after acute myocardial in-
farction. Leistner et al. [17] and Meyer et al. [15] recently
presented the 5 years’ follow-up data of the TOPCARE
AMI and BOOST trials respectively. Whereas in the first
report, in the absence of a control group, a persistent im-
provement in LVEF was shown for the patients treated with
BM-MNC, in the second report a decrease in LV function
either in the control or the BM-MNC group was demon-
strated by CMR.
Our data 4 months after AMI show recovery of LVEF by
8 absolute points in the BM-MNC treatment group and
by 4 absolute points in the control group. The effect was
maintained over time exclusively in the BM-MNC treated
group, whereas LVEF reduction occurred again in nearly
all BM-MNC untreated patients, resulting mainly from a
constant increase in LV diastolic volumes. While the differ-
ence between control and treatment group at 4 months was
not significant, at 60 months the absolute gain in LVEF is
significantly higher in the treated population as compared
with control.
The mechanism for improved myocardial function and sig-
nificant volume recovery after acute myocardial infarction
in patients treated by intracoronary injection of BM-MNC
has not been fully elucidated; it is however likely to be
chiefly related to paracrine effects leading to neoangiogen-
esis in the border zone of the myocardial scar. This mech-
anism has been reported to play a key role in preserving
myocardial function in the preclinical setting, as shown by
Olivetti et al. [18] and more recently by Yoon et al. [19]
reporting a direct correlation between myocardial recovery
from acute infarction and capillary density in the infarct
border zone. From a clinical point of view this may result
in improved microvascular function as described in a sub-
group of the Repair AMI trial [20], possibly resulting in
improved regional and global LV function in the short term
as shown by some [5, 6, 8, 10, 11] but not all studies pub-
lished so far. As for the Repair AMI study the improved
global LV-function resulted from an abrogation of negative
LV-remodelling shortly after the myocardial infarction
[21].
Another open question in cell therapy directly after AMI
is definition of the optimal time point for cell delivery.
The patients in the study presented were treated between
2004 and 2006, a time when little was known of this ar-
gument. The relatively early time-point chosen (a median
of 3 days after AMI) was, at that time, purely empirical.
Later on [22], on the basis of expert consensus, the ideal
time point for cell delivery was defined as 3–6 days after
AMI. More recently Traverse [23] showed that later treat-
ment (2–3 weeks after AMI) did not result in improved
left ventricular function compared to the control group. At
present two ongoing studies aim to settle the issue of the
optimal time point for BM-MNC administration, with res-
ults expected for late 2012 respectively: our own group is
co-organising a multicentre trial analysing early (5–7 days)
versus late (3–4 weeks) treatment [24], whereas another
group aims to compare BM-MNC injection either 3 days or
7 days after AMI [25].
The single centre study described presents several limita-
tions, such as small sample size and its open-labelled, non-
randomised design. This may have led to a selection bi-
as with a potentially higher compliance in the treatment
group, which may have an influence on long-term outcome
and may also explain the substantially higher proportion
of loss to follow-up in the control group. In addition, al-
though most of the difference lacks statistical significance,
the control group is not perfectly matched to the treatment
group, especially for a trend to a higher percentage of
3-vessel disease and higher age in the control group. Like-
wise, LVEDV and LVESV were significantly higher in
the treatment group with a trend towards a lower LVEF.
Furthermore, ischaemic post-conditioning, due to the tech-
nique of BM-MNC injection in the coronary artery, may
have had an effect on the patients in the treatment group.
However, after a search of the literature it remains unclear
whether this may help [26] or harm [27]. Most of the lim-
itations described may to some extent have influenced the
long-term results of the control group but to a much lesser
degree those of the active treatment group.
In conclusion, our series, representing one of the earliest
cell-based therapeutic approaches in Switzerland, may
provide additional evidence that BM-MNC therapy limits
the extent of ventricular remodelling after acute myocardial
infarction, extending current knowledge by showing that
the beneficial effect of BM-MNC is sustained by up to 5
years of follow-up. However, given the only moderate im-
provement in LV function after BM-MNC administration,
future research should focus on enhancing the regenerative
capacity of bone marrow-derived progenitor cells [28]. Al-
ternatively, given the limitations of autologous cell-based
therapy, the future of regenerative medicine may rather be
represented by an allogeneic approach, either by using “off
the shelf” mesenchymal stem cell products from young and
healthy donors [29] or by directly relying on the paracrine
effects of progenitor cells [30].
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Table 3: Baseline characteristics of the included patients and concomitant therapy.
Characteristic BM-MNC (N = 23) Control ( N = 19) P value
Risk factor
Age (years)
Mean 55 (10.5) 60.4 (10.9) 0.13
Median 56 60.5
Male sex – no. (%) 18 (78) 15 (79) 1.00
Hypertension – no. (%) 11 (48) 7 (36) 0.54
Hyperlipidaemia – no. (%) 21 (91) 17 (89) 1.00
Diabetes – no. (%) 3 (13) 2 (11) 1.00
Smoking (current or former) – no. (%) 15 (65) 11 (58) 0.75
Family history of CAD – no. (%) 6 (26) 5 (26) 1
Coronary artery disease – no. (%)
1-vessel disease 15 (65) 8 (42)
2-vessel disease 7 (30) 8 (42)
3-vessel disease 1 (4) 3 (16)
0.25
Infarct treatment
Primary PCI 20 (87) 18 (95)
Thrombolysis followed by accelerated PCI of the IRA 3 (13) 1 (5)
0.61
Infarct related vessel – no. (%)
LAD 23 (100) 19 (100) 1.00
LCX
RCA
PCI for additional stenoses in the non IRA – no. (%) 8 (35) 5 (26) 0.74
Time from symptom onset to first reperfusion therapy – hr
Mean 5.9 (3.9) 4.7 (2.5) 0.30
Median 4 4
TIMI flow before PCI
Mean 0.3 (0.5) 0.1 (0.5) 0.15
Median 0 0
DES – no. (%) 12 (52) 15 (79) 0.04
GP IIb/IIIa inhibitor during primary PCI – no. (%) 11 (48) 10 (53) 1.00
Intravenous catecholamines – no. (%) 5 (22) 1 (5) 0.20
Maximal CK - U/l
Mean 3,373 (2,029) 3,205 (2,047) 0.79
Median
Cell therapy
TIMI flow before study therapy
Mean 3 (0) – –
Median 3 – –
TIMI flow after study therapy
Mean 3 (0) – –
Median 3 – –
No. of injected cells – x10–6
Mean 158 (80) – –
Median 140 – –
Viability of cells – %
Mean 95 (2) – –
Baseline echocardiograpy
LVEF – %
Mean 41 (7) 45 (5) 0.11
Median 43 46
Enddiastolic volume – ml
Mean 118 (31) 101 (25) 0.06
Endsystolic volume – ml
Mean 68 (24) 56 (14) 0.04
Medication at discharge
Aspirin 23 (100) 19 (100) 1.00
Clopidogrel 23 (100) 19 (100) 1.00
ACE inhibitor or AT II blocker 17 (74) 16 (84) 0.48
Betablocker 16 (70) 15 (79) 0.73
Aldosterone antagonist 2 (9) 0 0.49
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Statin 21 (91) 18 (95) 1.00
Medication at 5 years FU
Aspirin and/or clopidogrel 21 (100) 11 (100) 1.00
ACE inhibitor or AT II blocker 17 (81) 8 (73) 0.92
Betablocker 13 (62) 6 (55) 0.87
Aldosterone antagonist 1 (5) 1(9) 0.49
Statin 18 (86) 8 (73) 0.90
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Figures (large format)
Figure 1
Study design and patient recruitment. AMI: acute myocardial infarction. PCI: percutaneous coronary intervention. i.c.: intracoronary. BM-MNC:
autologous bone marrow derived mononucleated cells. FU: follow-up.
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Figure 2
Left ventricular function directly after myocardial infarction (baseline), after 4 and 60 months. LVEF: left ventricular ejection fraction.
Figure 3
Left ventricular remodelling directly after myocardial infarction (baseline), after 4 and 60 months. LVEDV: left ventricular enddiastolic volume.
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Figure 4
Left ventricular remodelling directly after myocardial infarction (baseline), after 4 and 60 months. LVESV: left ventricular endsystolic volume.
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